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PCDH10 is epigenetically inactivated in multiple tumor types; however, studies in mature lymphoid malignancies are
limited. Here, we have investigated the presence of promoter hypermethylation of the PCDH10 gene in a large cohort of
well-characterized subsets of lymphomas. PCDH10 promoter hypermethylation was identified by methylation-specific PCR
in 57 to 100% of both primary B- and T-cell lymphoma specimens and cell lines. These findings were further validated by
Sequenom Mass-array analysis. Promoter hypermethylation was also identified in 28.6% cases of reactive follicular hyperpla-
sia, more commonly occurring in states of immune deregulation and associated with rare presence of clonal karyotypic
aberrations, suggesting that PCDH10 methylation occurs early in lymphomagenesis. PCDH10 expression was down regu-
lated via promoter hypermethylation in T- and B-cell lymphoma cell lines. The transcriptional down-regulation resulting
from PCDH10 methylation could be restored by pharmacologic inhibition of DNA methyltransferases in cell lines. Both T-
and B-cell lymphoma cell lines harboring methylation-mediated inactivation of PCDH10 were resistant to doxorubicin
treatment, suggesting that hypermethylation of this gene might contribute to chemotherapy response. VC 2013 Wiley
Periodicals, Inc.
INTRODUCTION
The protocadherin subfamily of the cadherin
superfamily of genes that encode cadherin-related
neuronal receptors plays a role in the establish-
ment and function of specific cell-cell connections
(Yagi, 2008). PCDH10, a member of this family,
has been implicated as tumor suppressor gene by
epigenetic inactivation in multiple human cancer
types (Ying et al., 2006, 2007; Narayan et al., 2009;
Yu et al., 2009; Cheung et al., 2010) and promoter
CpG island hypermethylation-associated PCDH10
gene silencing is a frequent event in myeloid and
lymphoid leukemias (Garcia-Manero et al., 2009;
Narayan et al., 2011). However, data regarding the
role of PCDH10 in mature lymphoid malignancies
are limited. Few reports have shown high fre-
quency of PCDH10 methylation and associated
down-regulation of expression in a limited panel
of T- and B-cell lymphoma cell lines and primary
tumors (Ying et al., 2007; Li et al., 2012).
Epigenetic processes, most notably patterns of
DNA promoter sequence hypermethylation, play
a central role in cellular transformation and treat-
ment of cancer. Specific genetic mutations that
confer chromatin modifications at certain loci have
led to the development of therapies influencing
the epigenetic landscape in leukemia (Nowak
et al., 2009; Baylin and Jones, 2011). Although
similar advances in malignant lymphoma are lack-
ing, recently there has been an intense growing
interest in understanding the role of epigenetic
modifications in lymphoid malignancies (Zain and
O’Connor, 2010; Seton-Rogers, 2012).
Additional Supporting Information may be found in the online
version of this article.
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Here, we have examined the presence of pro-
moter hypermethylation of PCDH10 in various his-
tologic subtypes of non-Hodgkin lymphoma
(NHL) and found high frequency methylation in
most lymphoma cases. Promoter hypermethylation
resulted in down-regulated expression of PCDH10
in lymphoma cell lines, and cell lines carrying
PCDH10 promoter methylation or down-regulated
expression exhibited resistance to doxorubicin
treatment. Furthermore, the presence of PCDH10
hypermethylation in a significant fraction of reac-
tive lymph nodes suggests that promoter methyla-
tion might be an early event in lymphomagenesis.
MATERIALS AND METHODS
Patient Samples and Cell Lines
A total of 292 DNA samples from 291 patients
derived from primary tumors diagnosed at our insti-
tute over a 12-year period (July 1997–June 2009)
were analyzed, which represented 21 reactive lymph
(RL) nodes exhibiting follicular hyperplasia (FH),
50 chronic lymphocytic leukemia/small lymphocytic
lymphomas (CLL/SLL), 19 Burkitt lymphomas
(BL), 39 follicular lymphomas (FL), 41 diffuse large
B-cell lymphomas (DLBCL), 38 marginal zone lym-
phomas (MZL), 16 mantle cell lymphomas (MCL),
35 multiple myelomas (MM), and 33 T/NK-cell
lymphomas. All specimens used in this study were
evaluated by morphology, flow cytometry, and cyto-
genetic analyses (Supporting Information Table 1)
and classified according to the current WHO criteria
(Swerdlow et al., 2008). All lymphoma cases were
selected to obtain >40% tumor cells either by mor-
phology and/or fluorescence in situ hybridization
(FISH) positivity. In addition, 10 T-cell lymphoma
cell lines (MT1, MT2, ED, CJ/M5, TLom1, SLB1,
HH, H9, HUT-78, and FE-PD) and 10 B-cell lym-
phoma cell lines (Raji, Daudi, LY-1, LY-3,
SU-DHL-4, SU-DHL-5, SU-DHL-8, SU-DHL-10,
WSU, and Farage) (kindly provided by Riccardo
Dalla-Favera, Columbia University, New York)
were also utilized. All cell lines were grown in
RPMI-1640 or IMDM medium containing 10 to
15% fetal bovine serum. Our institutional review
board approved the study protocol.
DNA and RNA Isolation
Frozen specimens and cell lines were utilized
for isolation of high molecular weight DNA and
RNA by standard methods. RNA quality and
quantity was assessed by a bioanalyzer (Agilent
Technologies, Foster City, CA).
Methylation Specific PCR (MSP)
Two micrograms of genomic DNA was con-
verted using EpiTect 96 bisulfite kit (Qiagen,
Valencia, CA). Placental DNA treated in vitro with
SssI methyltransferase (New England BioLabs,
Beverly, MA) and normal lymphocyte DNA con-
verted with sodium bisulfite was used as methyl-
ated and unmethylated controls, respectively. Four
sets of primers utilized for amplification of methyl-
ated (M) DNA and two sets of primers for unme-
thylated (U) DNA spanning two CpG islands
(CGIs) of cDNA clone NM-032961 were described
previously (Narayan et al., 2009, 2011). PCR was
performed using standard conditions for 3035
cycles with annealing temperatures varying
between 56 and 62C. All MSP experiments were
performed in triplicate and promoter hypermethyl-
ation was considered positive when present in at
least one of the regions in replicate experiments.
Sequenom EpiTyper Quantitative Methylation
Analysis
Quantitative methylation analysis was per-
formed using the Sequenom MALDI-TOF mass
spectrometry platform as per manufacturer specifi-
cations (Sequenom, Inc. San Diego, CA) and as
described previously (Narayan et al., 2011). Heat
maps were generated by using either R-script or
JMP genomics software (http://www.jmp.com/soft-
ware/genomics/).
Drug Treatment
Cells in culture were treated with 5 mM 5-aza-
20deoxycytidine (5-aza-CdR) for 5 days by replacing
the medium everyday, trichostatin (TSA) at a final
concentration of 200 nM for 24 hr and combination
of both as previously described (Narayan et al.,
2009). Cells collected from these experiments were
used for isolating total RNA. We determined
ICD50 values for all NHL cell lines for the drugs
used and the following final concentrations were
used in the present experiments: doxorubicin
(15 ng/ml), dexamethasone (100 nM), bortezomib
(2 ng/ml), methotrexate (50 nM), and L-asparagi-
nase (2 U/ml). Cell lines were treated with these
drugs for 48 hr to assess cell viability and apoptosis.
Reverse Transcription PCR (RT-PCR) and Western
Blot Analysis
Total RNA isolated from cell lines was reverse
transcribed as described (Narayan et al., 2009).
Semiquantitative expression of PCDH10 was
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performed in triplicate RT-PCR experiments
using the primers described previously and stand-
ard thermal cycle conditions (Narayan et al.,
2011). The b-actin gene was used as control to
assess the relative intensity of mRNA expression.
Western blot analysis was performed by standard
methods using polyclonal PCDH10 antibody
(Thermo Scientific, Rockford, IL) and a secondary
antibody conjugated with horseradish peroxidase
(Bio-Rad, Hercules, CA). Detection was per-
formed by ECL-Western Lightning Chemilumi-
nescence reagent (Amersham Pharmacia) and the
blot was re-probed with b-actin as control.
Cell Viability and Apoptosis Assays
Cell viability and cytotoxicity due to each drug
was assessed by standard MTT (3-(4,5-dime-
thylthiazol-2-yl)22,5-diphenyltetrazolium bro-
mide) (Invitrogen, Carlsbad, CA) colorimetric
assay. Briefly, 5,000 cells were seeded in 96-well
cell culture plates, grown overnight at 37C in 5%
CO2 incubator, and treated with drugs for 48 hr.
After incubation of cells in 5 mg/ml of MTT in
phosphate buffer saline for 3.5 hr, medium was
removed, the dye was dissolved in 150 ml of MTT
solvent and the optical density of solubilized form-
azan was assessed using a microplate reader (Bio-
Tek Quant, Winooski, VT). All treatments were
performed in four replicate wells in two independ-
ent experiments. To measure apoptosis, we used
Pacific BlueTM Annexin V/SYTOXVR AADvan-
cedTM Apoptosis Kit (Invitrogen). Briefly, 0.5 to
1.0 million cells were seeded in 48-well tissue cul-
ture plates, grown overnight at 37C at 5% CO2
incubator, and the indicated concentration of
drugs was added. Cells collected after 48 hr of
incubation were analyzed by a LSR II flow cytom-
eter (BD Biosciences, San Jose, CA) using 405 nm
and 488 nm excitation and 455 nm and 647 nm
emissions. A total of 20,000 events were analyzed
using Flowjo software (Tree Star, OR) in duplicate
experiments.
Karyotype and Fluorescence In Situ Hybridization
(FISH) Analyses
G-band karyotype and FISH analyses were per-
formed using standard methods.
Statistical Analysis
ANOVA and t-test statistics were calculated
using the GraphPad Prism software (LaJolla,
CA).
RESULTS
MSP Analysis Identifies High Frequency of PCDH10
Promoter hypermethylation in Various Histologic
Subtypes of Non-Hodgkin Lymphomas and
Multiple Myeloma
The PCDH10 gene promoter region spanning
two classic CpG islands was examined by MSP for
qualitative assessment of methylation as previ-
ously described (Supporting Information Fig. 1A)
(Narayan et al., 2011). Promoter methylation anal-
ysis was performed on a total of 292 DNA samples
derived from various histologic subtypes of B- and
T-cell lymphomas (Table 1). Among the B-cell
NHL, promoter hypermethylation was found in all
39 (100%) FL and 41 (100%) DLBCL, 18 (95%)
of 19 BL, 15 (94%) of 16 MCL, 34 (90%) of 38
MZL, 33 (66%) of 50 CLL, and 20 (57%) of 35
MM samples (Table 1). Among the 33 T- and
NK-cell lymphomas examined, 26 (79%) showed
promoter hypermethylation (Table 1). Similar
analysis on DNA isolated from 21 specimens of
reactive follicular hyperplasia revealed hypermeth-
ylation in six (29%) cases. Of note, 11 of these
cases occurred in individuals with known immune
deregulation and five displayed minor clonal kar-
yotypic abnormalities. Therefore, these data pro-
vide evidence that a large majority of cases across
all major histologic subtypes of lymphomas harbor
PCDH10 promoter hypermethylation and suggest
that inactivation of this gene may be related to dis-
ease pathogenesis. The presence of promoter
hypermethylation in reactive lymph nodes sug-
gests that DNA methylation modifications in
PCDH10 might be an early event in lymphoma-
genesis (Table 1). To examine if methylation is
uniformly present across the two CGIs or is
restricted to specific regions within a CGI, we
compared the patterns of MSP of the four regions
TABLE 1. Frequency of PCDH10 Promoter Hypermethylation









Chronic lymphocytic leukemia 50 33 (66%)
Burkitt’s lymphoma 19 18 (95%)
Follicular lymphoma 39 39 (100%)
Diffuse large B-cell lymphoma 41 41 (100%)
Marginal zone lymphoma 38 34 (90%)
Mantle cell lymphoma 16 15 (94%)
Multiple myeloma 35 20 (57%)
Natural killer (NK)/T-cell lymphoma 33 26 (79%)
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studied in each specific subtype of lymphoma.
This analysis revealed that promoter methylation
was restricted to smaller segments in CGIs in
cases of CLL and MM compared with extensive
methylation in other hisotologic subtypes
(Supporting Information Fig. 1B).
Validation of Promoter Methylation by
Quantitative High-Throughput MALDI-TOF MS
Analysis
To validate the MSP data and for quantitative
assessment of methylation, we analyzed 196 sam-
ples (20 RL/FH, 12 BL, 25 FL, 26 DLBCL, 38
MZL, 13 MCL, 27 MM, 14 CLL, and 21 T-/NK
cell) that were also analyzed by MSP, utilizing
high throughput MALDI-TOF MS methylation
analysis (Sequenom). For this analysis we chose
CpG Island 2 (CGI-2) covering 78 CpG sites in
three amplicons (Supporting Information Fig. 1A).
Of these, 47 CpG sites, which include single CpG
sites and multiple CpGs that fall in one fragment,
were considered informative after MALDI-TOF
MS read out and quality control analysis. Methyla-
tion fraction per CpG was calculated as described
previously (Narayan et al., 2011). Mean6 SEM
was 0.20186 0.03 for RL/FH specimens,
0.22936 0.03 for CLL, 0.20826 0.03 for MM,
0.31936 0.05 for MCL, 0.41096 0.04 for DLBCL,
0.54836 0.04 for BL, 0.35656 0.03 for FL,
0.34866 0.02 for MZL, and 0.30946 0.04 for
T-/NK cell cases (Fig. 1A). Differences in methyl-
ation levels between RL/FH samples and CLL
(P5 0.46) or MM (P 50.88) were not statistically
significant, while other histologic subtypes (BL,
DLBCL, FL, MZL, MCL, and T-NHL) showed
significant differences compared with RL/FH
samples (Fig. 1A). The levels of methylation were
highest in BL samples (P5 0.0001) among all the
histologic subtypes (Figs. 1A and 1B). Supervised
one-way hierarchical cluster analysis of RL/FH
samples in combination with each histologic sub-
type of NHL cases resulted in two or more major
clusters depending on the levels of methylation
(Fig. 1B, Supporting Information Fig. 2). In the
present analysis, we classified the top two clusters
as clusters 1 and 2, which contained cases harbor-
ing the highest levels of methylation, and the
remaining cases into one group. This analysis
showed that all the 12 cases of BL were present in
cluster 1 or 2, while only 4 of the 20 samples of
RL/FH were present in clusters 1 and 2. These
data suggest that PCDH10 promoter methylation
is high in BL samples as compared with RL/FH
samples (Fig. 1B, top panel). Similarly, a large
majority of samples from DLBCL, FL, MZL,
MCL, and T-NHL were grouped in cluster 1 or 2
along with 3 to 4 samples of RL (Fig. 1 and
Supporting Information Fig. 2). Nonsupervised
cluster analysis of all the samples together further
confirmed these findings where the same four RL/
FH samples were grouped with highest methyl-
ated lymphoma cases while the remaining 16 RL/
FH cases clustered with samples harboring low
methylation (Supporting Information Fig. 3). On
the other hand, only few samples from MM and
CLL appeared in cluster 1 and 2 along with three
to four samples of RL/FH (Supporting Informa-
tion Fig. 2). This observation is consistent with
the MSP data showing localized methylation in
CLL and MM samples. These data further sug-
gest that the PCDH10 promoter methylation levels
vary in different histologic subtypes of NHL.
PCDH10 Promoter Methylation Occurs Early in
Lymphomagenesis
As shown above, 29% of lymph nodes exhibiting
RL/FH displayed promoter hypermethylation by
MSP compared with >50% of cases in NHL histo-
logic subtypes and multiple myeloma (Table 1).
Similarly, Sequenom methylation analysis showed
0.2018 fraction of CpG methylation in RL/FH
lymph nodes. This level of methylation in RL/FH
is lower than most histologic subtypes of mature
lymphomas (Fig. 1 and Supporting Information
Fig. 2) and higher than normal bone marrow sam-
ples (3.6% by MSP and 0.115 methylation fraction
by Sequenom analysis) as reported previously
(Narayan et al., 2011). These data suggest that
PCDH10 promoter methylation occurs early in
lymphoma development. As stated above, hier-
archical cluster analysis of Sequenom MALDI-
TOF MS methylation data identified the same 4
of 20 RL/FH samples clustered with several histo-
logic subtypes of lymphoma samples exhibiting
higher methylation (Fig. 1B and Supporting Infor-
mation Figs. 2 and 3). This observation implies
that these 4 reactive lymph nodes harbor PCDH10
promoter methylation similar to high-grade lym-
phomas such as BL, DLBCL and MZL.
Of the 4 RL/FH samples that showed higher
methylation, 2 specimens were obtained from the
same patient’s adenoids and tonsils with previous
history of liver transplant and exhibited florid fol-
licular hyperplasia, without any evidence of NHL.
These 2 samples consistently grouped in cluster 1
or 2 by nonsupervised analysis. The adenoid
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sample showed a mean methylation fraction of
0.63 and the tonsil 0.45 by Sequenom methylation
analysis, which is similar to the methylation levels
seen in high-grade lymphomas (Fig. 1B and Sup-
porting Information Figs. 2 and 3). Karyotype
analysis identified the same chromosomal translo-
cation [t(1;14)(q21;q32)] in both adenoids and ton-
sils with the adenoids demonstrating a nonclonal
(1 of 41 metaphases) abnormality, while the tonsils
exhibited a minor clone (3 of 40 metaphases) har-
boring this translocation (Fig. 2A). The
t(1;14)(q21;q32) was reported in post-transplant
RL/FH (Vakiani et al., 2007) and has been shown
to be an early event in lymphomagenesis of
mature B-cell lymphomas. The breakpoint at
14q32 is being the site of the immunoglobulin
heavy chain (IGH) (Pinkerton et al.,1992; Dyomin
et al., 2000). FISH analysis using IGH break apart
Figure 1. Quantitative analysis of methylation of PCDH10 promoter
region in reactive lymphoid hyperplasia and various subtypes of lym-
phoma using Sequenom EpiTYPER. (A). Box-plot showing methylation
fraction in various lymphoma subtypes. Significant differences between
RL/FH and histologic subtype of lymphoma are shown by P value. Box
plot shows median, 25th and 75th percentile, minimum and maximum
values. (B). Heat maps showing one dimensional cluster analysis of
methylation data generated by Sequenom’s MassArray and EpiTyper
(left panel) between reactive lymph nodes analyzed with BL, DLBCL,
or MZL. Histogram shows number of cases present in each cluster
(right panel). CpG Units are arranged along the x-axis and samples are
on the y-axis. Right brackets in left panel indicate clusters of methyl-
ated cases. Missing data values are annotated in gray. The red and yel-
low scale at the bottom represents the percentage methylation with
dark red as lowest methylation and dark yellow as highest (100%)
methylation. BL, Burkitt lymphoma; C, cluster; CLL, chronic lympho-
cytic leukemia; DLBCL, diffuse large B-cell lymphoma; RL/FH, reactive
lymph node/follicular hyperplasia; FL, follicular lymphoma; MCL, mantle
cell lymphoma; MM, multiple myeloma; MZL, marginal zone lymphoma;
T-NHL, T-cell Non-Hodgkin lymphoma.
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probe (Vysis, Des Plaines, IL) showed low fre-
quency of rearrangement in both tonsils (1.8%)
and adenoids (0.8%). After 8 months of follow-up,
the patient presented with axillary and cervical
lymph node enlargement due to development of a
polymorphic post-transplant lymphoproliferative
disorder (PTLD), which was associated with
t(1;14) and an additional distinct cytogenetic
abnormality (trisomy 3) as major clones (Table 2;
Supporting Information Fig. 4A). The karyotypic
abnormalities were confirmed by FISH using IGH
break apart and centromere 3 probes (Vysis) (Fig.
2B and Supporting Information Fig. 4B). The axil-
lary lymph node showed IGH rearrangement in
20.4% cells and trisomy 3 in 16% cells, while the
cervical lymph node exhibited 20% cells with
IGH rearrangement and trisomy 3 in 14% cells
(Table 2). Methylation analysis on the follow-up
PTLD specimens could not be performed due to
lack of tissue availability. This case highlights the
fact that the methylation fraction in the RL/FH
sample was similar to the level seen in frank lym-
phomas while the chromosome aberration was pre-
senting a very low frequency that was almost
undetectable by FISH analysis. These data there-
fore suggest that the onset of promoter hyper-
methylation likely occurred prior to the origin of
the chromosome abnormality in this case and indi-
cate that PCDH10 methylation and potentially
other genes might precede chromosomal transloca-
tions in the development of lymphoma.
The third RL/FH specimen that showed high-
level of promoter methylation of PCDH10, which
occurred in an individual with FH, also demon-
strated a nonclonal cytogenetic abnormality by
karyotype, while FISH using IGH break apart
Figure 2. Cytogenetic analysis of a case of tonsils sample diagnosed as follicular hyperplasia
and subsequently progressed to post-transplant lymphoproliferative disorder (PTLD) on follow-
up. (A). A G-banded karyotype from tonsils showing t(1;14)(q21;q32) as indicated by arrows. (B).
FISH analysis showing IGH rearrangement in PTLD. Yellow arrow indicates intact IGH locus. Red
and green arrows indicated rearranged IGH.
TABLE 2. Histologic, Cytogenetic Abnormalities, and Methylation Changes Seen in Reactive Lymph Nodes Exhibiting High Pro-




S. No. Case Tissue Diagnosis MSP MassArray Karyotype IGH 13
1 RL305 Adenoids FH M 0.63 46,XY,t(1;14)(q21;q32)[1]/46,XY[40] 0.8 ND
RL306 Tonsils FH M 0.45 46,XY,t(1;14)(q21;q32)[3]/46,XY[57] 1.8 ND
F/U LN1294 LN-1 PTLD ND ND 46,XY,t(1;14)(q21;q32)[15]/47,XY,13[5] 20.4 16.0
F/U LN1295 LN-2 PTLD ND ND 46,XY,t(1;14)(q21;q32)[11]/47,XY,
13[10]/46,XY[2]
20.3 13.8
2 RL575 LN FH M 0.32 46,XX[20] 0 ND
3 RL717 Tonsil FH M 0.23 46,XY,t(5;14)(q31;q32)[1]/47,XY,1i(1)(q10),1
11,219[1]/46,XY[18]
0 ND
FISH, fluorescence in situ hybridization; FH, follicular hyperplasia; F/U, follow-up; LN, lymph node; M, methylated; MSP, methylation specific PCR;
ND, not done; PTLD, post-transplant lymphoproliferative disorder.
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probe was negative (Table 2). The fourth speci-
men with high levels of methylation occurred in
an individual with RL and showed neither a kar-
yotypic abnormality nor an IGH rearrangement.
No follow-up specimens from these two cases
were available. Of note, all the RL/FH samples
that showed a high methylation index were also
positive by MSP analysis.
PCDH10 Promoter Hypermethylation Correlates
with Down-regulated Expression and Pharmacologic
Inhibition of DNMTs Reactivates its Expression in
NHL Cell Lines
Since a large proportion of primary B- and
T-NHL cases harbored promoter methylation, we
examined the status of PCDH10 promoter hyper-
methylation in NHL cell lines. We tested 10
B-NHL cell lines and 10 T-NHL cell lines by the
MSP method. All the 20 cell lines exhibited
promoter methylation of one or both CGIs. Of the
10 B-NHL cell lines examined, both alleles were
methylated in both CGIs in all cell lines except
one. The cell line Farage showed presence of both
methylated and unmethylated alleles in CGI-2
(Fig. 3A, top panel). Among the T-NHL cell lines,
six cell lines (MT1, MT2, ED, TLom1, HH, and
FE-PD) showed only methylated alleles in both
CGI-1 and CGI-2. The remaining 4 T-NHL cell
lines (CJ/M5, SLB1, H9, and HUT-78) showed
both methylated and unmethylated alleles in CGI-
1 or CGI-2 (Fig. 3A, bottom panel). The cell lines
H9 and HUT-78 exhibited both CGIs with hetero-
zygous methylation, while the cell lines CJ/M5 and
SLB1 showed unmethylated CGI-1 and heterozy-
gous methylation in CGI-2.
Figure 3. Promoter methylation and expression analysis of
PCDH10 in NHL cell lines. (A). Methylation-specific PCR analysis of
PCDH10 in B- (top panel) and T- (bottom panel) NHL cell lines. MSP,
methylation specific PCR; U, unmethylated primer; M, methylated
primer. (B). Western blot showing PCDH10 protein expression. (C).
Analysis of mRNA expression by RT-PCR analysis to identify the effects
of treatment using inhibitors of methylation and HDAC in T-NHL cell
lines. A, azacytidine; ACTB, beta actin; A/T, azacytidine/trichostatin; T,
trichostatin; U, untreated; V1, variant 1.
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To examine the transcription levels of
PCHD10 in NHL cell lines, we performed RT-
PCR analysis of two PCDH10 transcript variants
(Variant 1 spanning exons 1 and 3; Variant 2 with
a single exon) on all cell lines. Since variant 2 is a
single intronless exon, RNA isolated from the
cell lines was treated with DNase to avoid DNA
amplification. All the 10 B-NHL cell lines exam-
ined failed to show any detectable levels of
expression of variant 1, while the variant 2 was
detected in three cell lines (Raji, SUDHL-5, and
LY-3). Of the 10 T-cell NHL cell lines, three
(MT1, TLom1, and HH) showed no detectable
expression of both variants. Detectable tran-
scripts of only variant 2 were found in four cell
lines (MT2, CJ/M5, ED, and SLB1) while variant
1 was undetectable. The remaining three cell
lines (H9, HUT-78, and FE-PD) showed detecta-
ble levels of expression of both variants. Western
blot analysis further confirmed that the protein
levels of PCDH10 were lacking or down-
regulated in all B- and T-NHL cell lines com-
pared with actin control (Fig 3B). Sixteen cell
lines showed very low expression, while the
remaining four cell lines (Daudi, Raji, SLB1, and
ED) showed relatively higher expression. These
data support the notion that PCDH10 expression
is down regulated in relation to promoter hyper-
methylation in the majority of NHL cell lines.
The cell line data combined with the data on pri-
mary NHL specimens confirm that PCDH10 pro-
moter hypermethylation is a common
phenomenon in mature lymphoma and multiple
myeloma.
Since down-regulated or complete lack of
expression of PCDH10 variant 1 was found in 17
of 20 NHL cell lines, we treated six T-NHL cell
lines (MT1, MT2, CJ/M5, ED, TLom1, and
SLB1) by the DNA demethylating agent 5-aza-
CdR and the HDAC inhibitor TSA to test the
reactivation of variant 1. Semi-quantitative RT-
PCR analysis exhibited reactivation of the
PCDH10 gene after 5-aza-CdR alone or in combi-
nation with TSA in all six cell lines (Fig. 3C). All
these cell lines showed PCDH10 methylation in
one or both alleles. None of the treatments had
any effect on the level of expression of the control
gene (Fig. 3C). Thus, these data establish that
demethylation of the PCDH10 promoter effec-
tively reactivates gene expression by reversing the
effect of methylation in cell lines. Overall, these
data demonstrate that PCDH10 down regulation in
the majority of NHL cell lines is a consequence of
promoter methylation.
PCDH10 Inactivation Results in Increased
Resistance to Doxorubicin in NHL Cell Lines
Since the DNA promoter methylation of spe-
cific genes plays a significant role in tumorigenic
processes and response to treatment, we examined
the effects of PCDH10 promoter methylation and
its associated gene silencing on treatment
response using a panel of NHL cell lines after
exposure to commonly used drugs for the treat-
ment of lymphoid malignancies. We tested all 20
NHL cell lines for cytotoxicity by MTT assay and
analyzed the data on the basis of methylation of
one or both alleles to defined doses of doxorubicin,
dexamethasone, bortezomib, methotrexate, and
L-asparaginase. Since all NHL cell lines showed
either one or both copies methylated, we used two
unmethylated leukemia cell lines (MOLT16 and
T-ALL) as controls (Narayan et al., 2011). The
only drug that showed differential cytotoxicity
based on the promoter methylation status was dox-
orubicin (Figs. 4A and 4B). Other drugs did not
exhibit detectable differences in cytotoxicity
based on methylation status (Supporting Informa-
tion Figs. 5A–5D). Of the 10 B-NHL cell lines
tested, nine had homozygous methylation and one
cell line (Farage) showed both methylated and
unmethylated alleles. The nine B-NHL cell lines
with homozygous methylation showed signifi-
cantly lower cytotoxic affects compared with the
cell line (Farage) that showed heterozygous meth-
ylation (P5 0.009). Both groups of B-NHL cell
lines were more resistant to doxorubicin treatment
compared with unmethylated leukemia cell lines
(Fig. 4A). Of the 10 T-NHL cell lines tested, six
cell lines showed homozygous methylation and
the other four cell lines showed heterozygous
methylation. Similar to the B-NHL cell lines, the
T-NHL cell lines with both methylated alleles
were significantly resistant to doxorubicin com-
pared with the heterozygous methylated cell lines
(P5 0.002) and unmethylated leukemia cell lines
(Fig. 4B). A similar trend for doxorubicin resist-
ance was found when the cell lines were analyzed
based on detectable transcripts of PCDH10 gene.
Of the nine B-NHL cell lines with complete
methylation, three cell lines (Raji, SUDHL-5, and
LY-3) showing detectable levels of PCDH10 tran-
scripts were significantly (P5 0.009) sensitive to
doxorubicin treatment compared with six cell lines
that showed no detectable levels of expression
(Fig. 4C). Similarly, seven T-NHL cell lines
(MT2, CJ/M5, ED, SLB1, H9, HUT-78, and FE-
PD) that showed detectable levels of variant 1 or 2
were more sensitive to doxorubicin treatment
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compared with three cell lines (MT1, TLom1,
and HH) that did not express PCDH10 (P5 0.01)
(Fig. 4D). Similar to methylation, other drugs did
not exhibit detectable differences in cytotoxicity
based on expression levels (Supporting Informa-
tion Figs. 5E–5H). These data suggest that
PCDH10 transcriptional down-regulation has a
causal affect on doxorubicin-induced cell lethality
in NHL cell lines.
We next asked if a similar difference in resist-
ance could be seen in the apoptotic response to
doxorubicin treatment. To examine this, we tested
two cell lines (H9 and HUT-78) expressing both
variants and two cell lines (SUDHL-8 and WSU)
with undetectable expression (Fig. 5A). The for-
mer had higher fraction of apoptotic cells com-
pared with nonexpressor cell lines after treatment
with doxorubicin (Fig. 5B). To examine further
the relationship between methylation status on
apoptotic response, we tested all the five drugs on
11 to 17 NHL cell lines. We found significantly
reduced apoptosis in all methylated NHL cell
lines compared with unmethylated leukemia cell
lines (Fig. 6). Also NHL cell lines with homozy-
gous methylation were significantly resistant to
apoptosis induction to dexamathasone and metho-
trexate treatments compared with the cell lines
that showed heterozygous methylation (Figs. 6B
and 6D). However, other drugs did not show sig-
nificant difference in apoptotic response based on
heterozygous and homozygous methylation status
(Figs. 6A, 6C, and 6E). These data suggest
Figure 5. Doxorubicin response to cell death by apoptosis analysis
in NHL cell lines in relation epigenetic silencing of PCDH10. (A). Flow
cytometric analysis of two cell lines showing high frequency of cell
death in PCDH10 expressed (H9) cell line compared with nonex-
pressed cell line (SUDHL-8). (B). Histogram showing significant differ-
ences cell death response to doxorubicin treatment in PCDH10
expressing cell lines compared with nonexpresser cell lines. Ctrl, Con-
trol; DOX, doxorubicin; V1/2, variant 1 and 2. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 4. Analysis of cell cytotoxicity in NHL cell lines exposed to
leukemic drugs in relation to methylation and silencing of PCDH10
gene. Viability assay showing cell survival in B-NHL (A) and T-NHL cell
lines (B) in relation to methylation status. Viability assay showing cell
survival in B-NHL cell lines (C) and T-NHL cell lines (D) in relation to
variant 2 mRNA expression. P values are shown above each compari-
son. UM/UM, both alleles unmethylated in leukemia cell lines; UM/M,
both unmethylated and methylated alleles present; M/M, both alleles
are methylated; V2-, no expression of variant 2; V21, detectable levels
of variant 2 expression.
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significantly reduced apoptotic response in
PCDH10 inactivated cell lines. Together, our data
demonstrate that methylation-mediated inactiva-
tion of PCDH10 negatively influences cellular
response to doxorubicin treatment and possibly
other drugs in NHL cell lines.
DISCUSSION
Cadherins play an important role in tumor pro-
gression by functioning as suppressors of invasion
and metastasis (Jeanes et al., 2008). The PCDH10
gene has shown to be inactivated by promoter
methylation in a variety of tumors (Waha et al.,
2005; Imoto et al., 2006; Yu et al., 2008, 2009; Nar-
ayan et al., 2009, 2011; Cheung et al., 2010). Over
expression of this gene significantly inhibits prolif-
eration of solid tumor cells in vitro, supporting its
tumor suppressor function (Ying et al., 2006). To
examine the role of PCDH10 in mature lymphoid
malignancies, we systematically analyzed qualita-
tive and quantitative promoter hypermethylation
in a large cohort of non-Hodgkin lymphomas,
including cell lines, and multiple myelomas. Our
present finding of high levels of promoter methyl-
ation in the vast majority of primary high-grade
mature B- and T-cell lymphomas and their
derived cell lines substantiate the prior findings
that PCDH10 is frequently methylated in different
subtypes of malignant lymphomas (Ying et al.,
2007). We have previously shown that epigenetic
changes in the promoter of PCDH10 preferentially
occur in lymphoid-lineage leukemias compared
with myeloid-lineage leukemias (Narayan et al.,
2011). The present findings combined with our
previous data suggest that PCDH10 methylation is
a unique phenomenon in all lymphoid lineage
hematologic malignancies. Furthermore, the iden-
tification of promoter hypermethylation in 29% of
RL/FH specimens and evidence of promoter
methylation preceding chromosomal translocation
in RL/FH suggest that inactivation of this gene
occurs early and is likely a critical alteration during
the neoplastic transformation of mature lymphoid
cells.
NHL represents a highly diverse group of
malignancies of both B- and T-cell lineages that
comprise of different histologic subtypes. The
malignant transformation of precursor cells is
driven by errors in the machinery that regulates
antibody diversification and lineage-specification
cause specific chromosomal translocations and
oncogenic mutations (Kuppers and Dalla-Favera,
2001). The landscape of genetic lesions in NHL is
highly characteristic of specific histologic subtypes
and several of the recurrent mutations have been
shown to be driver mutations that play a critical
role in lymphoma initiation (Shaffer et al., 2012).
More recent studies have uncovered structural
alterations in genes that regulate chromatin modi-
fications such as BMI1, EZH2, MLL2, CREBBP,
and EP300 (Shaffer et al., 2012). The natural
course of the different histologic subtypes of
NHL is highly variable, ranging from indolent,
like in CLL or FL, to highly aggressive, like in
BL. The prognosis is also highly variable to cur-
rent modalities of chemotherapy, radiation and the
anti-CD20 antibody (Rituximab) treatment
(Shaffer et al., 2012). Although specific genetic
changes are diagnostic of specific lymphoma, bio-
markers of therapeutic response are lacking in
NHL.
DNA methylation and chromatin modifications
dictate the biological behavior and response to
therapy of cancer cells. Although, in the present
study, we identified PCDH10 methylation in
Figure 6. Flow cytomety analysis of apoptotic response in NHL
(both B- and T-) cell lines exposed to leukemic drugs in relation to
methylation of PCDH10 gene. Histograms showing apoptotic response
after exposure to doxorubicin (A, 17 cell lines), dexamethasone (B, 15
cell lines), bortezomib (C, 15 cell lines), methotrexate (D, 11 cell
lines), L-asparaginase (E, 15 cell lines). P values are shown above each
comparison. UM/UM, both alleles unmethylated in leukemia cell lines;
UM/M, both unmethylated and methylated alleles present; M/M, both
alleles are methylated.
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various NHL histologic subtypes, it was more fre-
quently observed in lymphomas showing evidence
of germinal center transit (BL, FL, DLBCL,
MZL, and MCL) and T-cell lymphomas com-
pared with nongerminal center origin lymphomas
(CLL and MM). Moreover, the levels of promoter
methylation were not significantly different among
indolent (FL) and aggressive (BL and DLBCL)
type lymphomas. Based on these observations,
combined with the finding that reactive lymph
nodes harboring high-level methylation could pro-
gresses to frank lymphoma, we propose a hypothe-
sis that PCDH10 methylation might represent an
important early event in lymphomagenesis.
Although the role of PCDH10 in cancer has not
been fully elucidated, evidence for the epigenetic
silencing of this gene contributing to tumorigene-
sis has been established (Ying et al., 2006). More
recently, PCDH10 was reported to be methylated
in early stages of gastric carcinogenesis and its
methylation was associated with poor prognosis in
gastric cancer patients (Yu et al., 2009). Since
PCDH10 is a target of epigenetic silencing in the
majority of lymphomas, its implications for chemo-
therapy response was examined. Although the
mechanisms underlying cellular resistance to apo-
ptosis in lymphomas remain unclear, our finding of
resistance to cytotoxicity and decreased apoptotic
response to doxorubicin treatment suggests that
PCDH10 methylation and inactivation in cell lines
might play a role in chemotherapy resistance.
Doxorubicin, a cellular target of topoisomerase-2
(Top2), is a widely used chemotherapeutic drug in
many cancer types, including lymphomas. Doxoru-
bicin binds to both DNA and Top2 forming
doxorubicin-DNA adducts that initiates caspase
cascade dependent apoptosis (Swift et al., 2006).
The biologic basis of PCDH10-related resistance
mechanisms and cooperation with other genetic/
epigenetic pathways in chemoresistance of NHL
remains to be determined. Ultimately designing
successful epigenetic induction therapies similar
to myeloid leukemias is a major challenge for ther-
apy involving epigenetic agents in NHL.
In summary, this study has demonstrated the
occurrence of epigenetic silencing of PCDH10 in a
high proportion of NHL and its likely onset at an
early stage of lymphomagenesis suggesting a role
for PCDH10 in lymphoma development. The find-
ing of doxorubicin resistance in association with
PCDH10 inactivation may have relevance in fur-
ther exploring the role of epigenetic alterations
and ultimately in establishing epigenetic therapies
in lymphomas.
REFERENCES
Baylin SB, Jones PA. 2011. A decade of exploring the cancer epi-
genome—Biological and translational implications. Nat Rev
Cancer 11:726–734.
Cheung HH, Lee TL, Davis AJ, Taft DH, Rennert OM, Chan
WY. 2010. Genome-wide DNA methylation profiling reveals
novel epigenetically regulated genes and non-coding RNAs in
human testicular cancer. Br J Cancer 102:419–427.
Dyomin VG, Palanisamy N, Lloyd KO, Dyomina K, Jhanwar SC,
Houldsworth J, Chaganti RS. 2000. MUC1 is activated in a
B-cell lymphoma by the t(1;14)(q21;q32) translocation and is
rearranged and amplified in B-cell lymphoma subsets. Blood 95:
2666–2671.
Garcia-Manero G, Yang H, Kuang SQ, O’Brien S, Thomas D,
Kantarjian H. 2009. Epigenetics of acute lymphocytic leukemia.
Semin Hematol 46:24–32.
Imoto I, Izumi H, Yokoi S, Hosoda H, Shibata T, Hosoda F,
Ohki M, Hirohashi S, Inazawa J. 2006. Frequent silencing of
the candidate tumor suppressor PCDH20 by epigenetic mech-
anism in non-small-cell lung cancers. Cancer Res 66:4617–
4626.
Jeanes A, Gottardi CJ, Yap AS. 2008. Cadherins and cancer: how
does cadherin dysfunction promote tumor progression? Onco-
gene 27:6920–6929.
Kuppers R, Dalla-Favera R. 2001. Mechanisms of chromosomal
translocations in B cell lymphomas. Oncogene 20:5580–5594.
Li Y, Yang ZS, Song JJ, Liu Q, Chen JB. 2012. Protocadherin-10
is involved in angiogenesis and methylation correlated with
multiple myeloma. Int J Mol Med 29:704–710.
Narayan G, Scotto L, Neelakantan V, Kottoor SH, Wong AH,
Loke SL, Mansukhani M, Pothuri B, Wright JD, Kaufmann
AM, Schneider A, Arias-Pulido H, Tao Q, Murty VV. 2009. Pro-
tocadherin PCDH10, involved in tumor progression, is a fre-
quent and early target of promoter hypermethylation in cervical
cancer. Genes Chromosomes Cancer 48:983–992.
Narayan G, Freddy AJ, Xie D, Liyanage H, Clark L, Kisselev S,
Un Kang J, Nandula SV, McGuinn C, Subramaniyam S,
Alobeid B, Satwani P, Savage D, Bhagat B, Murty VV. 2011.
Promoter methylation-mediated inactivation of PCDH10 in
acute lymphoblastic leukemia contributes to chemotherapy
resistance. Genes Chromosomes Cancer 50:1043–1053.
Nowak D, Stewart D, Koeffler HP. 2009. Differentiation therapy
of leukemia: 3 Decades of development. Blood 113:3655–3665.
Pinkerton PH, Reis MD, DeCoteau J, Srigley JR, Dube ID,
London B. 1992. A lineage-specific t(1;14)(q21;q32) as an early
event in development of B-cell clonal expansion. Cancer Genet
Cytogenet 64:166–169.
Seton-Rogers S. 2012. Lymphoma: Epigenetic therapy gains
momentum. Nat Rev Cancer 12:798–799.
Shaffer AL, 3rd, Young RM, Staudt LM. 2012. Pathogenesis of
human B cell lymphomas. Annu Rev Immunol 30:565–610.
Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H,
Thiele J, Vardiman JW. 2008. WHO Classification of Tumours
of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon,
France: International Agency for Research on Cancer. pp. 180–
319.
Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM. 2006.
Doxorubicin-DNA adducts induce a non-topoisomerase II-
mediated form of cell death. Cancer Res 66:4863–4871.
Vakiani E, Nandula SV, Subramaniyam S, Keller CE, Alobeid B,
Murty VV, Bhagat G. 2007. Cytogenetic analysis of B-cell
posttransplant lymphoproliferations validates the World Health
Organization classification and suggests inclusion of florid fol-
licular hyperplasia as a precursor lesion. Hum Pathol 38:315–
325.
Waha A, Guntner S, Huang TH, Yan PS, Arslan B, Pietsch T,
Wiestler OD. 2005. Epigenetic silencing of the protocadherin
family member PCDH-gamma-A11 in astrocytomas. Neoplasia
7:193–199.
Yagi T. 2008. Clustered protocadherin family. Dev Growth Differ
50(Suppl 1):S131–S140.
Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, Putti
T, Murray P, Chan AT, Tao Q. 2006. Functional epigenetics
identifies a protocadherin PCDH10 as a candidate tumor sup-
pressor for nasopharyngeal, esophageal and multiple other carci-
nomas with frequent methylation. Oncogene 25:1070–1080.
Ying J, Gao Z, Li H, Srivastava G, Murray PG, Goh HK, Lim CY,
Wang Y, Marafioti T, Mason DY, Ambinder RF, Chan AT, Tao
Q. 2007. Frequent epigenetic silencing of protocadherin 10 by
1040 NARAYAN ET AL.
Genes, Chromosomes & Cancer DOI 10.1002/gcc
methylation in multiple haematologic malignancies. Br J Hae-
matol 136:829–832.
Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian
LW, Wong YP, Tong JH, Ying JM, Jin H, To KF, Chan FK,
Sung JJ. 2009. Methylation of protocadherin 10, a novel tumor
suppressor, is associated with poor prognosis in patients with
gastric cancer. Gastroenterology 136:640–651.
Yu JS, Koujak S, Nagase S, Li CM, Su T, Wang X, Keniry M,
Memeo L, Rojtman A, Mansukhani M, Hibshoosh H, Tycko B,
Parsons R. 2008. PCDH8, the human homolog of PAPC, is a candi-
date tumor suppressor of breast cancer. Oncogene 27: 4657–4665.
Zain J, O’Connor OA. 2010. Targeting histone deacetyalses in the
treatment of B- and T-cell malignancies. Invest New Drugs
28(Suppl 1):S58–S78.
PCDH10 PROMOTER METHYLATION IN LYMPHOMA 1041
Genes, Chromosomes & Cancer DOI 10.1002/gcc
